| Assessment Status | Rapid Review Complete |
| HTA ID | 20058 |
| Drug | Avatrombopag |
| Brand | Doptelet® |
| Indication | For the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
| Assessment Process | |
| Rapid review commissioned | 16/12/2020 |
| Rapid review completed | 15/02/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that avatrombopag not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations October 2021.
